Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 5;6(9):e2335511.
doi: 10.1001/jamanetworkopen.2023.35511.

New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk

Chenan Liu  1   2   3   4 , Tong Liu  1   2   3   4 , Qingsong Zhang  5 , Pingping Jia  1   2   3   4 , Mengmeng Song  6 , Qi Zhang  7 , Guotian Ruan  1   2   3   4 , Yizhong Ge  1   2   3   4 , Shiqi Lin  1   2   3   4 , Ziwen Wang  1   2   3   4 , Hailun Xie  1   2   3   4 , Jinyu Shi  1   2   3   4 , Ruiqin Han  8 , Yue Chen  1   2   3   4 , Xin Zheng  1   2   3   4 , Liuyi Shen  9 , Li Deng  3   4 , Shouling Wu  10 , Hanping Shi  1   2   3   4
Affiliations

New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk

Chenan Liu et al. JAMA Netw Open. .

Abstract

Importance: The onset age of nonalcoholic fatty liver disease (NAFLD) is decreasing, and whether earlier ages of NAFLD onset are associated with increased cancer risk is currently unclear.

Objective: To explore the association between NAFLD new-onset age and cancer risk.

Design, setting, and participants: This cohort study was conducted among 179 328 participants included in the Kailuan Cohort Study between 2006 and 2021. In total, 46 100 incident NAFLD cases were identified. For each case, a participant matched by age (older or younger by 1 year) and sex was randomly selected to create a new matched study cohort. Data were analyzed from December 2022 through April 2023.

Exposure: Onset of NAFLD.

Main outcomes and measures: The association between the onset age of NAFLD and the risk of different cancer types was evaluated using weighted Cox regression models. Population-attributable fractions (PAFs) were used to quantify the association of NAFLD with cancer risk at different ages.

Results: Among 63 696 participants (mean [SD] age, 51.37 [12.43] years; ‭10 932 females [17.2%] and ‭52 764 males [82.8%]), 31 848 individuals had NAFLD and 31 848 individuals were in the control group. During a median (IQR) follow-up of 10.16 (7.89-11.67) years, 2415 patients were diagnosed with cancer. Compared with the matched group, patients aged less than 45 years at NAFLD onset exhibited a higher risk of cancer (average hazard ratio [AHR], 1.52; 95% CI, 1.09-2.12), and as the onset age of NAFLD increased, the cancer risk decreased (ages 45-54 years: AHR, 1.50; 95% CI, 1.15-1.97; ages 55-64 years: AHR, 1.13; 95% CI, 0.97-1.33; ages >65 years: AHR, 0.75; 95% CI, 0.45-1.27; P for interaction < .001). Among patients aged less than 45 years at NAFLD onset, cancers were mainly digestive system and lung cancers, with AHR values of 2.00 (95% CI, 1.08-3.47) and 2.14 (95% CI, 1.05-4.36), respectively. PAFs also showed that in patients aged less than 45 years at NAFLD onset, 17.83% (95% CI, 4.92%-29.86%) of cancer risk was attributable to NAFLD.‬‬‬‬.

Conclusions and relevance: This study found that NAFLD was associated with increased cancer risk and there was an interaction with onset age, such that the younger the onset age of NAFLD, the greater the cancer risk.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Study Flowchart
NAFLD indicates nonalcoholic fatty liver disease.
Figure 2.
Figure 2.. Risk of Cancer by Age Group
Average hazard ratios with 95% CIs of all cancer types and digestive system cancers are presented among participants with new-onset NAFLD vs controls across age groups. The model was adjusted for age (continuous), sex (categorical), body mass index (continuous; calculated as weight in kilograms divided by height in meters squared), waist circumference (continuous), total cholesterol level (continuous), triglyceride level (continuous), total bilirubin level (continuous), hypersensitive C-reactive protein level (continuous), alanine aminotransferase level (continuous), smoking status (categorical), physical activity (categorical), hypertension (categorical), diabetes (categorical), gallbladder polyps (categorical), and gallstone disease (categorical). NAFLD indicates nonalcoholic fatty liver disease.
See this image and copyright information in PMC

References

    1. Lazarus JV, Mark HE, Anstee QM, et al. ; NAFLD Consensus Consortium . Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60-78. doi:10.1038/s41575-021-00523-4 - DOI - PubMed
    1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. doi:10.1002/hep.29466 - DOI - PMC - PubMed
    1. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42. doi:10.1038/nrgastro.2016.147 - DOI - PubMed
    1. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901-910. doi:10.1016/S2213-8587(14)70032-4 - DOI - PubMed
    1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1)(suppl):S47-S64. doi:10.1016/j.jhep.2014.12.012 - DOI - PubMed

Publication types